These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37421190)

  • 41. Predictors at diagnosis for start of biologic disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis: a cohort study.
    Hameed M; Exarchou S; Eberhard A; Sharma A; Bergström U; Cagnotto G; Einarsson JT; Turesson C
    BMJ Open; 2024 Feb; 14(2):e076131. PubMed ID: 38382962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers.
    Cordtz RL; Hawley S; Prieto-Alhambra D; Højgaard P; Zobbe K; Overgaard S; Odgaard A; Kristensen LE; Dreyer L
    Ann Rheum Dis; 2018 May; 77(5):684-689. PubMed ID: 29247125
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
    Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
    Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment.
    Chen MH; Lee MH; Liao HT; Chen WS; Lai CC; Tsai CY
    Clin Rheumatol; 2018 Feb; 37(2):429-438. PubMed ID: 29307092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy.
    Solomon DH; Xu C; Collins J; Kim SC; Losina E; Yau V; Johansson FD
    Arthritis Res Ther; 2021 Jan; 23(1):26. PubMed ID: 33446261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
    Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors of long-term clinical remission in rheumatoid arthritis.
    Fornaro M; Cacciapaglia F; Lopalco G; Venerito V; Iannone F
    Eur J Clin Invest; 2021 Feb; 51(2):e13363. PubMed ID: 32725883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
    Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
    BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Cho SK; Lee J; Han M; Bae SC; Sung YK
    Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
    Gabay C; Riek M; Scherer A; Finckh A;
    Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up].
    Aronova ES; Lukina GV; Glukhova SI; Gridneva GI; Kudryavtseva AV
    Ter Arkh; 2020 Jun; 92(5):39-45. PubMed ID: 32598774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
    Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C
    Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.
    Seror R; Lafourcade A; De Rycke Y; Pinto S; Castaneda J; Fautrel B; Mariette X; Tubach F
    RMD Open; 2022 Jun; 8(2):. PubMed ID: 35738803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study.
    Dormuth CR; Fisher A; Hudson M; Austin PC; Ernst P; Bresee L; Chateau D; Tamim H; Paterson JM; Lafrance JP; Taylor-Gjevre RM; Platt RW; Canadian Network For Observational Drug Effect Studies Cnodes Investigators
    Semin Arthritis Rheum; 2021 Dec; 51(6):1291-1299. PubMed ID: 34462128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).
    Shi Q; Li KJ; Treuer T; Wang BCM; Gaich CL; Lee CH; Wu WS; Furnback W; Tang CH
    PLoS One; 2018; 13(4):e0193489. PubMed ID: 29624580
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
    Espinoza F; Le Blay P; Combe B
    J Rheumatol; 2017 Jun; 44(6):844-849. PubMed ID: 28412711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
    Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study.
    Abtahi S; Cordtz R; Dreyer L; Driessen JHM; Boonen A; Burden AM
    Am J Med; 2022 Jul; 135(7):879-888.e3. PubMed ID: 35134369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.